In the Media

November 1, 2018

Cannabinoid Based Pharmaceutical Product May Help Rare Skin Disease

InMed is a bio-pharmaceutical company that specializes in the research, development and commercialization of cannabinoid based pharmaceutical products. We take this class of compounds known as cannabinoids and we formulate these into disease specific products to treat diseases with high unmet medical needs.

Source: BTV

Share this post

Latest Articles

Benzinga: Pharmaceutical Cannabinoids and their Impact on Treatments for Complex Diseases

InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu, join the Benzinga Small Cap Conference Panel Discussion “Pharmaceutical Cannabinoids and their Impact on Treatments

October 6, 2021

The Dales Report – InMed Pharmaceuticals Positioned For Growth As Cannabinoid Supply Sales Poised For Imminent “Take Off”

Shadd Dales of The Dales Report interviews InMed CEO, Eric A. Adams, on the fast-growing synthesized cannabinoid industry and the market opportunity of rare cannabinoids.

September 22, 2021

InMed and BayMedica Host First Webinar Together Following News of Signing Definitive Agreement on Acquisition

InMed and BayMedica hosted a live webinar to talk about InMed’s acquisition of BayMedica, how it positions the company as a leader in the manufacturing

September 16, 2021